AbbVie Inc (NYSE:ABBV) – AbbVie Announces Initiation of Pivotal Phase III Study of Veliparib (ABT-888) for Patients with Non-Small Cell Lung Cancer

[PR Newswire] – NORTH CHICAGO, Ill., April 15, 2014 /PRNewswire/ — AbbVie (NYSE: ABBV) announced the initiation of a global Phase III clinical trial evaluating the safety and efficacy of its investigational compound, . . . → Read More: AbbVie Inc (NYSE:ABBV) – AbbVie Announces Initiation of Pivotal Phase III Study of Veliparib (ABT-888) for Patients with Non-Small Cell Lung Cancer Similar Articles: Company Update: AbbVie Inc (NYSE:ABBV) – AbbVie to Host First-Quarter Earnings Conference Call Stock Update: Pfizer Inc (NYSE:PFE) – Pfizer lung cancer drug fails in two large studies AbbVie Inc. (NYSE:ABBV) ~ AbbVie’s hepatitis C treatment helps 96 pct of patients in trial